Free Trial

Immunovant (IMVT) Competitors

Immunovant logo
$15.53 -0.63 (-3.90%)
Closing price 04:00 PM Eastern
Extended Trading
$16.12 +0.59 (+3.80%)
As of 05:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IMVT vs. SLNO, QGEN, BBIO, MRNA, VRNA, ELAN, ROIV, RVMD, GRFS, and RYTM

Should you be buying Immunovant stock or one of its competitors? The main competitors of Immunovant include Soleno Therapeutics (SLNO), QIAGEN (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Grifols (GRFS), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "medical" sector.

Immunovant vs. Its Competitors

Soleno Therapeutics (NASDAQ:SLNO) and Immunovant (NASDAQ:IMVT) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability.

In the previous week, Soleno Therapeutics had 31 more articles in the media than Immunovant. MarketBeat recorded 38 mentions for Soleno Therapeutics and 7 mentions for Immunovant. Immunovant's average media sentiment score of 1.19 beat Soleno Therapeutics' score of 0.59 indicating that Immunovant is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Soleno Therapeutics
8 Very Positive mention(s)
1 Positive mention(s)
14 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Positive
Immunovant
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Soleno Therapeutics has a beta of -2.71, suggesting that its stock price is 371% less volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500.

Soleno Therapeutics' return on equity of -73.74% beat Immunovant's return on equity.

Company Net Margins Return on Equity Return on Assets
Soleno TherapeuticsN/A -73.74% -56.67%
Immunovant N/A -80.99%-72.23%

Soleno Therapeutics is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Soleno TherapeuticsN/AN/A-$175.85M-$4.14-12.36
ImmunovantN/AN/A-$413.84M-$2.85-5.45

97.4% of Soleno Therapeutics shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 6.4% of Soleno Therapeutics shares are held by insiders. Comparatively, 1.8% of Immunovant shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Soleno Therapeutics currently has a consensus target price of $115.09, indicating a potential upside of 124.92%. Immunovant has a consensus target price of $33.60, indicating a potential upside of 116.36%. Given Soleno Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Soleno Therapeutics is more favorable than Immunovant.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Soleno Therapeutics
0 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
3.08
Immunovant
0 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.83

Summary

Soleno Therapeutics beats Immunovant on 9 of the 13 factors compared between the two stocks.

Get Immunovant News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMVT vs. The Competition

MetricImmunovantMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.71B$3.11B$5.75B$10.27B
Dividend YieldN/A2.32%5.72%4.60%
P/E Ratio-5.4521.4075.1726.41
Price / SalesN/A240.57455.9688.49
Price / CashN/A44.4425.8129.91
Price / Book3.739.6413.256.28
Net Income-$413.84M-$53.20M$3.29B$270.38M
7 Day Performance-5.13%0.51%0.76%2.79%
1 Month Performance2.04%4.34%4.63%6.00%
1 Year Performance-47.66%9.40%73.44%25.97%

Immunovant Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMVT
Immunovant
2.4547 of 5 stars
$15.53
-3.9%
$33.60
+116.4%
-45.5%$2.71BN/A-5.45120Positive News
SLNO
Soleno Therapeutics
4.433 of 5 stars
$72.30
+3.6%
$115.09
+59.2%
+1.5%$3.71BN/A-17.4630Positive News
Short Interest ↑
Analyst Revision
QGEN
QIAGEN
4.4431 of 5 stars
$47.62
+0.1%
$49.69
+4.4%
+0.5%$10.57B$1.98B28.135,765
BBIO
BridgeBio Pharma
4.4155 of 5 stars
$54.29
+1.7%
$63.35
+16.7%
+95.6%$10.20B$221.90M-13.27400Analyst Forecast
MRNA
Moderna
4.5363 of 5 stars
$24.83
-1.2%
$42.88
+72.7%
-65.6%$9.78B$3.24B-3.305,800
VRNA
Verona Pharma PLC American Depositary Share
2.3184 of 5 stars
$106.30
0.0%
$109.00
+2.5%
+257.4%$9.20B$42.28M-107.3730Positive News
ELAN
Elanco Animal Health
2.6289 of 5 stars
$19.02
+3.2%
$17.33
-8.9%
+28.0%$9.16B$4.44B22.129,000Positive News
ROIV
Roivant Sciences
3.1565 of 5 stars
$12.91
-0.1%
$16.38
+26.8%
+17.9%$8.82B$29.05M0.00860
RVMD
Revolution Medicines
4.1949 of 5 stars
$41.06
+1.4%
$72.00
+75.4%
+6.5%$7.57B$11.58M-9.12250Analyst Forecast
Analyst Revision
GRFS
Grifols
4.0879 of 5 stars
$10.11
-0.2%
$10.30
+1.9%
+6.7%$6.96B$7.81B8.6423,822
RYTM
Rhythm Pharmaceuticals
3.2989 of 5 stars
$99.77
-2.3%
$101.57
+1.8%
+93.9%$6.78B$130.13M-33.15140Positive News

Related Companies and Tools


This page (NASDAQ:IMVT) was last updated on 9/15/2025 by MarketBeat.com Staff
From Our Partners